Matrixx Initiatives Files Presentation with SEC Regarding Offer To Acquire ProPhase Labs

Matrixx Initiatives today announced that it has filed a presentation with the Securities and Exchange Commission ("SEC") in connection with its revised offer to acquire ProPhase Labs, Inc.

.  Separately today, Matrixx announced it has increased its offer to acquire all of the outstanding shares of ProPhase by 14.3% to $1.60 per share, and has sent a letter to the ProPhase Board of Directors. Matrixx believes that its revised all-cash offer, which is not contingent on financing, is highly attractive to ProPhase shareholders, as it provides them with compelling upfront and certain value relative to a difficult, uncertain and highly speculative multi-year turnaround program recently outlined by  ProPhase's management.  Matrixx's presentation outlines the significant challenges ProPhase faces by remaining a standalone entity, including: ProPhase is in a Vulnerable Market Position ProPhase lacks scale to effectively compete in the highly competitive Cough Shortening / Immune Boosting market. ProPhase's most comparable competitors generate 3.5x more in annual revenue and are backed by owners with substantial resources. ProPhase has an Unsustainable Financial Model ProPhase